News Releases

Date Title and Summary View
Sep 10, 2020
Sep 02, 2020
Sep 02, 2020
Aug 21, 2020
U.S. FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Approval broadens DARZALEX label to include fifth treatment option in the relapsed/refractory setting and represents the eighth approved indication for DARZALEX HORSHAM, Pa., August 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S.
Aug 20, 2020
Aug 19, 2020
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
$6.5 Billion Acquisition Through an All-Cash Tender Offer of $52.50 Per Momenta Share   Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases   Momenta's Cambridge, Massachusetts, Presence Increases J&J Footprint and
Aug 17, 2020
Aug 14, 2020
Aug 05, 2020
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Company working  to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with
Aug 03, 2020
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.